Octreoscan (Indium In-111 Pentetreotide)

Octreoscan is employed in the diagnostic pathway for somatostatin receptor‑positive neuroendocrine tumors. It assists clinicians in tumor localization, staging and therapy planning.

• Gastroenteropancreatic neuroendocrine tumors: helps locate primary and metastatic disease for treatment planning.
• Bronchial carcinoid tumors: enables detection of primary and nodal involvement.
• Medullary thyroid carcinoma: assists in identifying somatostatin‑positive lesions for surgical and therapeutic decision‑making.

• Indium In-111 Pentetreotide is a radiolabelled somatostatin analog that binds with high affinity to somatostatin receptor subtypes 2 and 5 on the surface of neuroendocrine cells. After intravenous injection, the complex is internalized, and the indium‑111 radioisotope emits gamma photons that are captured by gamma‑camera imaging, producing a map of receptor‑rich tissue distribution.

Adverse reactions are generally mild and related to the radiopharmaceutical nature of the product.

Common Side Effects

• Nausea: mild, transient discomfort.
• Flushing: brief reddening of the face or neck.
• Headache: mild to moderate intensity.
• Injection site pain: brief soreness at the IV site.
• Transient hypotension: temporary drop in blood pressure.
• Mild fatigue: short‑lasting tiredness.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rapid onset breathing difficulty and rash.
• Significant hypotension: prolonged low blood pressure requiring intervention.
• Radiation‑induced marrow suppression: decreased blood cell counts.
• Renal toxicity: impaired kidney function in susceptible patients.
• Pulmonary embolism: rare clot formation following injection.
• Severe skin reactions: extensive rash or Stevens‑Johnson‑like presentation.

Octreoscan should be administered only after confirming patient suitability and reviewing relevant medical history.

• Pregnancy testing: avoid use in pregnant women unless benefits outweigh risks.
• Breastfeeding: discontinue breastfeeding for an appropriate period after administration.
• Renal function: assess kidney function; adjust protocol for impaired clearance.
• Prior allergic reactions: evaluate history of hypersensitivity to radiopharmaceuticals.
• Concomitant chemotherapy: consider cumulative radiation exposure.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreoscan may interact with other agents that influence radiation exposure or somatostatin pathways.

Major Interactions (Avoid)

• High‑dose peptide receptor radionuclide therapy (PRRT): additive radiation burden.
• Radiolabeled antibodies: concurrent administration may increase overall radiation dose.

Moderate Interactions (Monitor Closely)

• Somatostatin analog therapy (e.g., octreotide): may compete for receptor binding.
• Nephrotoxic drugs (e.g., cisplatin): heightened risk of renal toxicity.
• Antihistamines: may mask early signs of an allergic reaction.
• Diuretics: could alter renal clearance of the radiopharmaceutical.
• Calcium channel blockers: potential impact on vascular tone affecting distribution.